Endomyocardial Biopsy Market size

Endomyocardial Biopsy Market size was valued at USD 321.5 million in 2022 and is estimated to account for USD 619.2 million by 2032. An endomyocardial biopsy is a medical procedure used to obtain a small sample of tissue from the inner lining of the heart, known as the endocardium.

This procedure is typically performed to diagnose and monitor certain heart conditions, especially those that involve inflammation, infection, rejection after heart transplantation, or other disorders that affect the heart muscle or its lining. Technological advancements in medical imaging, catheterization techniques, and biopsy tools can enhance the accuracy, safety, and efficiency of endomyocardial biopsies.

The growing prevalence of cardiovascular diseases is a major driving factor for the industry. Cardiovascular diseases, such as heart failure, cardiomyopathies, and myocarditis, continue to be a significant global health concern. For instance, as per the World Health Organization (WHO), cardiac diseases are the number one cause of death globally, accounting for an estimated 20.5 million deaths in 2021. Further, the incidence of cardiovascular diseases is increasing, partially due to factors such as sedentary lifestyle, unhealthy diet, tobacco use, obesity, and an increasing aging population base.

COVID-19 Impact

The COVID-19 pandemic initially had a negative impact on the endomyocardial biopsy market, with healthcare systems prioritizing COVID-19 cases and postponing non-urgent procedures. Fear of infection and restrictions on movement further contributed to a decline in elective medical tests such as endomyocardial biopsies. Moreover, due to lockdowns, travel restrictions, and concerns regarding potential exposure to the virus, several individuals postponed routine screenings and follow-up visits. This led to a decline in the number of procedures being performed, affecting the utilization of endomyocardial biopsy products.

Endomyocardial Biopsy Market Trends

The increasing number of heart transplants globally has led to a greater demand for endomyocardial biopsies. Endomyocardial biopsies are commonly performed after heart transplantations to monitor for rejection and other complications. An increase in the number of heart transplant surgeries contribute to the increasing demand for biopsies. According to the United Network for Organ Sharing, in 2022, nearly 42,887 organ transplants were performed in the U.S. Among these transplants, 8,409 were heart transplants.

Furthermore, the growing adoption of minimally invasive procedures in the field of cardiology has positively impacted the industry. Minimally invasive techniques are preferred by both patients and healthcare providers owing to its several advantages including smaller incisions, reduced post-operative pain, faster recovery times, shorter hospital stays, and lower risk of complications.

Learn more about the key segments shaping this market

Download Free Sample

The endomyocardial biopsy market by product is categorized into forceps and accessories. The forceps segment garnered USD 229.3 million revenue size in the year 2022. Procedures for endomyocardial biopsy (EMB) frequently involve the use of forceps. The development of new and improved forceps with better grip and precision is increasing the demand for forceps in endomyocardial biopsy procedures. Additionally, forceps are offered in a variety of sizes and shapes to accommodate the requirements of various patients and operations.

Learn more about the key segments shaping this market

Download Free Sample

Based on tip, the endomyocardial biopsy market is segmented into maxi-curved, straight, pre-curved and others. The straight segment accounted for over 36% market share in the year 2022. The straight tip design offers precise and targeted biopsy, enhancing manoeuvrability within the heart's chambers. Its compatibility with catheters enables a minimally invasive approach, leading to faster patient recovery. Furthermore, the real-time visualization feature and adaptability to various patient anatomies make it a versatile and widely accepted choice.

Based on end-use, the endomyocardial biopsy market is segmented into hospital, ambulatory surgical centers, and others. The hospital segment accounted for over 51% market share in the year 2022. Hospitals with active heart transplant programs require regular and thorough monitoring of transplant recipients to detect early signs of rejection. Furthermore, the growing number of hospitals around the world is expected to drive industry expansion as more people gain access to healthcare services.

Looking for region specific data?

Download Free Sample

U.S. endomyocardial biopsy market accounted for USD 109 million revenue size in 2022. The progression is majorly attributable to rapid technological advancements in products, highly advanced, and well-established healthcare infrastructure with specialized cardiac centers and cutting-edge medical facilities. This enables the efficient and widespread adoption of endomyocardial biopsy procedures. Furthermore, the U.S. actively focuses on heart transplantation programs, driving the demand for regular endomyocardial biopsies to monitor transplant recipients.

Endomyocardial Biopsy Market Share

Some of the eminent industry participants operating in the endomyocardial biopsy market include :

• Argon Medica Devices, Inc
• Cordis
• Mermaid Medical
• Terumo Corporation
• Scholten Surgical Instruments, Inc.
• Changzhou Lookmed Medical Instrument Co., Ltd.
•  Medtronic plc
• Boston Scientific Corporation
• Teleflex Incorporated,
• Cook Medical LLC
•  Merit Medical Systems

Endomyocardial Biopsy Industry News:

• In February 2020, Teleflex Corporation completed the acquisition of IWG High Performance Conductors, Inc. (HPC), a prominent manufacturer specializing in minimally invasive medical products and high-performance conductors. Such acquisitions broaden the product portfolio of the company.
  
• In July 2019, Argon Medical Devices, Inc. announced that it had entered into a definitive license agreement with Hatch Medical, L.L.C. ("Hatch Medical"), granting exclusive global rights for marketing and distributing the Scorpion TIPS Access Systems. Thus, such acquisitions enable businesses to expand their presence.
  

Endomyocardial Biopsy market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Product (USD Million & Units)

• Forceps
• Accessories

By Tip (USD Million)

• Maxi-curved
• Straight
• Pre-curved
• Others

By End-use (USD Million)

• Hospitals
• Ambulatory surgical centers
• Others

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Switzerland
  • The Netherlands
  • Denmark
  • Poland
  • Sweden
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • New Zealand
  • Thailand
  • Vietnam
  • Indonesia
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Chile
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Turkey